21 November 2022 : Clinical Research
Long-Term Effect of Pancreaticoduodenectomy Combined with Revascularization for Resectable Pancreatic Carcinoma in Elderly Patients
Jiali Yang1ABCDEF, Zhengrong Xu2ABCD, Junfeng Zhang1CD, Yao Zheng1CD, Jianyou Gu1AC, Qiang Zhou1CD, Xianxing Wang1CD, Shixiang Guo1DF, Hongyu Zhang3AD, Shengkai Chen1ADG*, Huaizhi Wang1ADGDOI: 10.12659/MSM.938443
Med Sci Monit 2022; 28:e938443
Table 4 Analysis of the OS and PFS of PDAC patients who underwent PDR according to age.
| Variables | OS | |||
|---|---|---|---|---|
| Age <60 y (n=97) | 60 y ≤ Age <70 y (n=51) | Age ≥70 y (n=22) | P value | |
| Preoperative CA19-9 ≥200 IU/L | 9.2 (7.638–10.762) | 7.1 (3.892–10.308) | 8.1 (3.587–12.613) | 0.474 |
| Vascular invasion site | ||||
| PV | 14.7 (0.000–33.238) | – | 17.9 (6.858–28.942) | 0.436 |
| Confluence of PV-SMV | 7.2 (5.343–9.057) | 8.9 (6.401–11.399) | 7.0 (4.690–9.310) | 0.673 |
| SMV | 11.5 (8.386–14.614) | 8.4 (5.619–11.181) | 9.1 (4.941–13.259) | 0.049 |
| Venous reconstruction | ||||
| Interposition graft | 9.7 (8.771–10.629) | 7.1 (5.566–8.634) | 6.1 (0.220–11.980) | 0.628 |
| End-to-end anastomosis | 9.6 (7.717–11.283) | 9.2 (7.048–11.352) | 8.3 (6.469–10.131) | 0.693 |
| Primary closure | 14.7 (0.000–40.063) | – | – | 0.293 |
| T stage 1/2 | 11.2 (8.595–13.805) | 8.9 (7.783–9.927) | 9.1 (5.253–12.947) | 0.509 |
| N stage 1/2 | 9.2 (5.764–12.636) | 8.4 (6.051–10.749) | 5.9 (0.000–12.968) | 0.833 |
| TNM stage | ||||
| I/II | 9.7 (7.718–11.682) | 8.9 (7.845–9.955) | 10.8 (7.267–14.333) | 0.736 |
| III/IV | 7.1 (1.329–12.871) | 6.7 (3.580–9.820) | 3.0 (0.439–5.561) | 0.479 |
| Degree of differentiation | ||||
| Well | 12.1 (8.278–15.922) | 6.1 (5.620–6.580) | 10.9 (0.000–34.329) | 0.345 |
| Moderate | 9.9 (8.036–11.735) | 10.1 (8.395–11.805) | 8.3 (6.750–9.850) | 0.451 |
| Poor | 5.8 (5.143–6.457) | 6.9 (5.256–8.544) | 4.3 (0.000–11.982) | 0.977 |
| Postoperative adjuvant antineoplastic therapy | 14.7 (9.175–20.225) | 9.2 (5.973–12.427) | 13.1 (8.591–17.609) | 0.184 |
| ( | ≤ | ≥ ( | ||
| Preoperative CA19-9 ≥200 IU/L | 6.3 (4.389–8.211) | 5.0 (2.805–7.195) | 6.5 (0.000–13.679) | 0.957 |
| Vascular invasion site | ||||
| PV | 7.1 (2.353–11.847) | – | 17.9 (6.858–28.942) | 0.095 |
| Confluence of PV-SMV | 5.0 (3.793–6.207) | 6.0 (4.736–7.264) | 5.7 (3.904–7.496) | 0.998 |
| SMV | 7.6 (6.362–8.838) | 6.2 (1.586–10.814) | 8.4 (4.395–9.057) | 0.226 |
| Venous reconstruction | ||||
| Interposition graft | 5.9 (2.491–9.309) | 4.6 (3.723–5.477) | 5.7 (0.000–11.580) | 0.397 |
| End-to-end anastomosis | 6.9 (6.444–7.356) | 7.8 (4.997–10.603) | 8.3 (4.870–11.730) | 0.740 |
| Primary closure | 12.4 (0.000–34.020) | – | – | 0.303 |
| T stage 1/2 | 7.8 (6.549–9.051) | 6.1 (3.303–8.897) | 8.4 (4.747–12.053) | 0.854 |
| N stage 1/2 | 5.3 (3.287–7.313) | 5.8 (3.804–7.796) | 3.0 (0.000–8.544) | 0.879 |
| TNM stage | ||||
| I/II | 7.0 (5.808–8.192) | 6.0 (4.671–7.329) | 9.1 (5.744–12.456) | 0.472 |
| III/IV | 4.0 (0.945–7.055) | 6.7 (2.021–11.379) | 3.0 (0.439–5.561) | 0.711 |
| Degree of differentiation | ||||
| Well | 6.7 (0.624–12.776) | 6.1 (5.620–6.580) | 10.9 (0.000–36.345) | 0.416 |
| Moderate | 7.0 (5.622–8.378) | 8.2 (5.818–10.582) | 8.3 (4.271–12.329) | 0.918 |
| Poor | 5.0 (3.028–6.972) | 4.0 (2.708–5.292) | 4.3 (0.000–9.485) | 0.225 |
| Postoperative adjuvant antineoplastic therapy | 7.9 (6.230–9.570) | 6.0 (3.849–8.151) | 11.0 (6.921–15.079) | 0.281 |
| Postoperative adjuvant therapy includes chemotherapy, radiotherapy, biological therapy, traditional Chinese medicine therapy, etc. | ||||